Results 141 to 150 of about 1,701 (184)

Lenacapavir: A Capsid Inhibitor for HIV-1 Treatment and Prevention

Biochemical Pharmacology
Lenacapavir (GS-6207) is a capsid inhibitor approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced people with multidrug-resistant HIV-1. Here, this study provides a comprehensive overview of lenacapavir, with a particular focus on its long-acting properties, pharmacodynamics ...
Yelin Deng, Ewelina Król, Guangdi Li
exaly   +3 more sources

Subtypes A1 and D, and Recombinant HIV-1 Natural Polymorphisms Associated With Lenacapavir Drug Resistance in Uganda [PDF]

Journal of Antimicrobial Chemotherapy
BACKGROUND: Lenacapavir, a novel HIV-1 capsid inhibitor, shows promise for treating MDR HIV-1, as well as for pre-exposure prophylaxis (PrEP) in prevention of HIV infection.
Daniel Omoding, Guinevere Q Lee
exaly   +4 more sources

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

New England Journal of Medicine
BACKGROUND: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men ...
Colleen F Kelley, Jesse L. Clark, Richard M Novak   +2 more
exaly   +3 more sources

Drug-Drug Interactions Potential With the HIV-1 Capsid Inhibitor Lenacapavir [PDF]

Expert Opinion on Drug Metabolism and Toxicology
IntroductionLenacapavir is the first HIV-1 capsid inhibitor administered subcutaneously twice yearly. While lenacapavir is currently only indicated as salvage therapy, it has the potential to become a foundation of future treatments and to revolutionize ...
Catia Marzolini, Saye Khoo, Sara Gibbons
exaly   +2 more sources

Lenacapavir (Sunlenca) for Multidrug-Resistant HIV

The Medical Letter on Drugs and Therapeutics, 2023
The FDA has approved oral and injectable formulations of the HIV-1 capsid inhibitor lenacapavir (Sunlenca – Gilead) for use with other antiretroviral drugs to treat multidrug-resistant HIV-1 infection (MDR-HIV) in heavily treatment-experienced adults whose current regimen is failing.
openaire   +2 more sources

Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV

Annals of Pharmacotherapy, 2023
Objective: To review the efficacy, safety, and role of lenacapavir (LEN) in the treatment of HIV-1 infection. Data Sources: A literature search was performed using PubMed and Google Scholar (through March 2023) with the search term LEN
Marylee W. Tailor, Elias B. Chahine, David Koren, Elizabeth M. Sherman   +3 more
openaire   +2 more sources

Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People With Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial

Clinical Infectious Diseases
Background Lenacapavir is a long-acting human immunodeficiency virus type 1 (HIV-1) capsid inhibitor for treatment of HIV-1 infection. We evaluated the efficacy and safety of lenacapavir in combination with an investigator-selected optimized background ...
Onyema Ogbuagu, Jason Brunetta, Hadas Dvory-Sobol   +2 more
exaly   +2 more sources

HIV Community Welcomes Lenacapavir Deal

Lancet, The
Sophie Cousins
exaly   +2 more sources

Lenacapavir Sodium

American Journal of Health-System Pharmacy, 2023
openaire   +2 more sources

Lenacapavir in first-line therapy

The Lancet HIV, 2023
openaire   +2 more sources